Hippocampal atrophy in cerebral amyloid angiopathy (CAA) has been reported to be similar to that in Alzheimer’s disease (AD).
Objective:
To evaluate if CAA pathology partly mediates reduced hippocampal volume in patients with AD.
Methods:
Patients with a clinical diagnosis of AD and neuropathological confirmation of AD+/-CAA in the National Alzheimer’s Coordinating Center database were included in the study. The volumes of temporal lobe structures were calculated on T1-weighted imaging (T1-MRI) using automated FreeSurfer software, from images acquired on average 5 years prior to death. Multivariate regression analysis was performed to compare brain volumes in four CAA groups. The hippocampal volume on T1-MRI was correlated with Clinical Dementia Rating sum of boxes (CDRsb) score, apolipoprotein E (APOE) genotype, and hippocampal atrophy at autopsy.
Results:
The study included 231 patients with no (n = 45), mild (n = 70), moderate (n = 67), and severe (n = 49) CAA. Among the four CAA groups, patients with severe CAA had a smaller mean left hippocampal volume (p = 0.023) but this was not significant when adjusted for APOE ɛ4 (p = 0.07). The left hippocampal volume on MRI correlated significantly with the hippocampal atrophy grading on neuropathology (p = 0.0003). Among patients with severe CAA, the left hippocampal volume on T1-MRI: (a) decreased with an increase in the number of APOE ɛ4 alleles (p = 0.04); but (b) had no evidence of correlation with CDRsb score (p = 0.57).
Conclusion:
Severe CAA was associated with smaller left hippocampal volume on T1-MRI up to five years prior to death among patients with neuropathologically confirmed AD. This relationship was dependent on APOE ɛ4 genotype.
FotiadisP, van RoodenS, van der GrondJ, SchultzA, Martinez-RamirezS, AurielE, ReijmerY, van OpstalAM, AyresA, SchwabKMAlzheimer’s Disease Neuroimaging IHeddenT, RosandJ, ViswanathanA, WermerM, TerwindtG, SperlingRA, PolimeniJR, JohnsonKA, van BuchemMA, GreenbergSM, GurolME (2016) Cortical atrophy in patients with cerebral amyloid angiopathy: A case-control study. Lancet Neurol15, 811–819.
8.
KimJ, NaHK, ShinJH, KimHJ, SeoSW, SeongJK, NaDL (2018) Atrophy patterns in cerebral amyloid angiopathy with and without cortical superficial siderosis. Neurology90, e1751–e1758.
9.
SuboticA, McCrearyCR, SaadF, NguyenA, Alvarez-VeronesiA, ZwiersAM, CharltonA, BeaudinAE, IsmailZ, PikeGB, SmithEE (2021) Cortical thickness and its association with clinical cognitive and neuroimaging markers in cerebral amyloid angiopathy. J Alzheimers Dis81, 1663–1671.
10.
JakelL, De KortAM, KlijnCJM, SchreuderF, VerbeekMM (2022) Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. Alzheimers Dement18, 10–28.
11.
NitkunanA, LanfranconiS, CharltonRA, BarrickTR, MarkusHS (2011) Brain atrophy and cerebral small vessel disease: A prospective follow-up study. Stroke42, 133–138.
MontineTJ, PhelpsCH, BeachTG, BigioEH, CairnsNJ, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, TrojanowskiJQ, VintersHV, HymanBTNationalInstitute on Aging; Alzheimer’s Association (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: A practical approach. Acta Neuropathol123, 1–11.
18.
HymanBT, PhelpsCH, BeachTG, BigioEH, CairnsNJ, CarrilloMC, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, ThiesB, TrojanowskiJQ, VintersHV, MontineTJ (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement8, 1–13.
BesserLM, KukullWA, TeylanMA, BigioEH, CairnsNJ, KoflerJK, MontineTJ, SchneiderJA, NelsonPT (2018) The Revised National Alzheimer’s Coordinating Center’s Neuropathology Form-available data and new analyses. J Neuropathol Exp Neurol77, 717–726.
21.
OlichneyJM, HansenLA, HofstetterCR, LeeJH, KatzmanR, ThalLJ (2000) Association between severe cerebral amyloid angiopathy and cerebrovascular lesions in Alzheimer disease is not a spurious one attributable to apolipoprotein E4. Arch Neurol57, 869–874.
22.
VonsattelJP, MyersRH, Hedley-WhyteET, RopperAH, BirdED, RichardsonEPJr., (1991) Cerebral amyloid angiopathy without and with cerebral hemorrhages: A comparative histological study. Ann Neurol30, 637–649.
23.
DaleAM, FischlB, SerenoMI (1999) Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage9, 179–194.
24.
FischlB, SalatDH, BusaE, AlbertM, DieterichM, HaselgroveC, van der KouweA, KillianyR, KennedyD, KlavenessS, MontilloA, MakrisN, RosenB, DaleAM (2002) Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron33, 341–355.
25.
BenjaminiY, HochbergY (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B Methodol57, 289–300.
26.
HashimotoM, YasudaM, TanimukaiS, MatsuiM, HironoN, KazuiH, MoriE (2001) Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer’s disease. Neurology57, 1461–1466.
27.
ManningEN, BarnesJ, CashDM, BartlettJW, LeungKK, OurselinS, FoxNCAlzheimer’s Disease NeuroImaging Initiative (2014) APOE epsilon4 is associated with disproportionate progressive hippocampal atrophy in AD. PLoS One9, e97608.
28.
CorderEH, SaundersAM, StrittmatterWJ, SchmechelDE, GaskellPC, SmallGW, RosesAD, HainesJL, Pericak-VanceMA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science261, 921–923.
29.
DrzezgaA, GrimmerT, HenriksenG, MuhlauM, PerneczkyR, MiedererI, PrausC, SorgC, WohlschlagerA, RiemenschneiderM, WesterHJ, FoerstlH, SchwaigerM, KurzA (2009) Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology72, 1487–1494.
SaundersAM, StrittmatterWJ, SchmechelD, George-HyslopPH, Pericak-VanceMA, JooSH, RosiBL, GusellaJF, Crapper-MacLachlanDR, AlbertsMJ, et al. (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology43, 1467–1472.
AbushakraS, PorsteinssonAP, SabbaghM, BracoudL, SchaererJ, PowerA, HeyJA, ScottD, SuhyJ, TolarMAlzheimer’s Disease Neuroimaging Initiative (2020) APOE epsilon4/epsilon4 homozygotes with early Alzheimer’s disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline. Alzheimers Dement (N Y)6, e12117.
42.
CharidimouA, Martinez-RamirezS, ShoamaneshA, Oliveira-FilhoJ, FroschM, VashkevichA, AyresA, RosandJ, GurolME, GreenbergSM, ViswanathanA (2015) Cerebral amyloid angiopathy with and without hemorrhage: Evidence for different disease phenotypes. Neurology84, 1206–1212.
43.
KnudsenKA, RosandJ, KarlukD, GreenbergSM (2001) Clinical diagnosis of cerebral amyloid angiopathy: Validation of the Boston criteria. Neurology56, 537–539.
